Ischemic Hepatitis in a Patient with Congestive Cardiomyopathy: An Innovative Approach to Therapy Using Intravenous Dobutamine

Daniel K. Levy, Jonathan M. Schwartz, William H. Frishman, Michael L. Schwarz, Thierry H. LeJemtel

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Patients who sustain a transient period of hypotension or low cardiac output can develop massive elevations of the serum transaminases without serum markers of acute hepatitis, a recent myocardial infarction or exposure to toxins and chemicals. This condition is often termed “ischemic hepatitis” (IH), with its pathological correlate being centrilobular necrosis. Recognition of IH can help in the appropriate management of these patients, and avoid unnecessary diagnostic testing. The authors describe a patient with congestive cardiomyopathy in whom IH developed as part of a complicated hospital course. The condition appeared to reverse with the administration of dobutamine, suggesting inotropic therapy as an appropriate treatment modality. 1994 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)270-272
Number of pages3
JournalThe Journal of Clinical Pharmacology
Volume34
Issue number3
DOIs
StatePublished - Mar 1994

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Ischemic Hepatitis in a Patient with Congestive Cardiomyopathy: An Innovative Approach to Therapy Using Intravenous Dobutamine'. Together they form a unique fingerprint.

Cite this